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Introduction: Recent data on influenza C virus indicate 
a possible higher clinical impact in specified patient 
populations than previously thought. Aim: We aimed 
to investigate influenza C virus circulation in Germany. 
Methods: A total of 1,588 samples from 0 to 4 year-old 
children presenting as outpatients with influenza-like 
illness (ILI) or acute respiratory infection were analysed 
retrospectively. The samples represented a subset of all 
samples from the German national surveillance system 
for influenza in this age group in 2012–14. The pres-
ence of influenza C virus was investigated by real-time 
PCR. For positive samples, information on symptoms 
as well as other respiratory virus co-infections was 
considered. Retrieved influenza C viral sequences were 
phylogenetically characterised. Results: Influenza C 
viral RNA was detected in 20 (1.3% of) samples, includ-
ing 16 during the 2012/13 season. The majority (18/20) 
of influenza C-positive patients had ILI according to the 
European Union definition, one patient had pneumonia. 
Viruses belonged to the C/Sao Paulo and C/Kanagawa 
lineages. Most (11/20) samples were co-infected with 
other respiratory viruses. Conclusion: Our data are the 
first on influenza C virus circulation in Germany and 
notably from a European national surveillance system. 
The low detection frequency and the identified virus 
variants confirm earlier observations outside a surveil-
lance system. More virus detections during the 2012/13 
season indicate a variable circulation intensity in the 
different years studied. Influenza C virus can be con-
sidered for ILI patients. Future studies addressing its 
clinical impact, especially in patients with severe dis-
ease are needed.
Introduction
Influenza viruses are a major threat to human health 
and are therefore in the focus of national and inter-
national health authorities. Among these, influenza 
virus types A and B are the main considered, as they 
cause annual epidemics with high morbidity and con-
siderable mortality [1]. In contrast, influenza C virus 
has been regarded as a pathogen of minor relevance, 
causing mild or clinically unapparent disease [2,3]. 
Nevertheless, in recent years, detections of influenza 
C in hospitalised young children with (severe) lower 
respiratory tract disease were reported [4-9]. Thus, the 
clinical and epidemiological significance of this virus 
species might have been underestimated and needs to 
be reassessed.
In Europe, the burden of influenza C virus infection in 
children and adults is largely unknown, as no system-
atic surveillance data are available. The few studies 
published mainly focus on clinical data, mostly from 
hospitalised children [4,9,10]. In Germany, no surveil-
lance data and no sequence information on circulating 
influenza C viruses have ever been reported. Therefore, 
we decided to search for influenza C in our outpatient 
sample collection assembled for the purpose of influ-
enza virus surveillance in Germany. As young chil-
dren are described to have the highest infection rates 
[6,7,11], we confined our study to the 0–4 year-old age 
group. We furthermore sequenced the haemagglutinin 
esterase (HE) gene from influenza C-positive samples 
to phylogenetically characterise the detected viruses.
Methods
Clinical samples
All samples were collected from practitioners partici-
pating in the national influenza surveillance, who are 
distributed over the complete German territory and 
represent a statistically valid proportion of the German 
population [12]. These practitioners continuously collect 
nasal or throat swabs from non-hospitalised patients 
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presenting with symptoms of influenza-like illness (ILI) 
according to the European Union (EU) definition or an 
acute respiratory infection (ARI). An ILI case is defined 
by a sudden disease onset with at least one of four sys-
temic symptoms (fever or feverishness, malaise, head-
ache, myalgia) and at least one of three respiratory 
symptoms (cough, sore throat, shortness of breath) 
[13], while ARI is an acute respiratory disease with at 
least one of the four following symptoms: fever, cough, 
rhinorrhoea or sore throat. The samples are sent to the 
German National Influenza Centre, accompanied by a 
completed questionnaire on patient characteristics, 
sampling date, disease symptoms, influenza vaccina-
tion status and therapeutic intervention i.e. antiviral 
treatment. They are routinely analysed for influenza 
virus types A and B, human respiratory syncytial virus 
(RSV) as well as – since April 2013 – human adenovirus 
(AdV), metapneumovirus (HMPV) and rhinovirus (HRV). 
All samples are stored at -80 °C afterwards.
For this study, a subset of 1,588 samples (66.9%) was 
selected from a total number of 2,377 samples taken 
from children ≤ 4 years of age in the years 2012–14 as 
described in the supplementary file (Supplement S1). 
Briefly, at least every second sample in a chronologi-
cal order was retrospectively analysed for influenza C 
virus. To extend the basis for the co-infection data, all 
influenza C-positive samples were additionally tested 
for human parainfluenza viruses types 1–4 and corona-
viruses OC43, NL63, HKU1 and 229E. Positive samples 
taken before April 2013 were furthermore retrospec-
tively examined for AdV, HMPV and HRV.
Ethical statement
The conduct of a sentinel surveillance is covered 
by German legislation (§13, §14, Protection against 
Infection Act). The German national surveillance of 
influenza and other respiratory viruses was further-
more approved by an ethical committee of the Charitè 
Berlin (application number EA2/126/11). Additionally, 
for all samples a written consent was given for their 
inclusion in research studies. All analyses were done 
with pseudonymised data.
Sample preparation, nucleic acid extraction and 
cDNA synthesis
After their arrival in the laboratory, 3mL of cell cul-
ture medium (minimum essential medium (MEM) with 
Table 1
List of oligonucleotide sequences used in the study
Assay name Oligonucleotide name Oligonucleotide sequence (5’–3’) Amount in nM Method
FluC NP qPCR
FluC NP F1068 GCRTGCTTTGGRCTTGCTTATG 600
qPCRFluC NP R1161 ARTTTCCTATTTTCATTCTGTTTCTCAAC 600
FluC NP TM1100 FAM – TTTGGTYTCTGCYATGGTYAGCCAYCCTCT - BHQ1 200
FCV qPCR (IC)
FCV F54 CGTTACCGCCACACCCAT 300
qPCRFCV R141 GAGTTCACGAAAGATTTCAGACCAT 300
FCV TM96 LC610 - ACCCATCATTCTAACACTCCCGCCAAT - BHQ1 100
HE fragment 1
FluC HE F1 AGCAGAAGCAGGGGKTTAATAATG 500
nPCR
FluC HE F7 AGCAGGGGTTTAATAATGTTTTTCTC 500
FluC HE R866 CCAGAATTCCCTGTGTAAGGTGA 500
FluC HE R895 ATCATGTCACATTGCATTGTTGG 500
FluC HE F477 CCAGAAAARCATYTATGAATTGGC 500
Seq
FluC HE R353 CCAGGTGGGCCAAACATACT 500
HE fragment 2
FluC HE F714 GCATCTTGTGGCTTCTTGCTATT 500
nPCR
FluC HE F722 TGGCTTCTTGCTATTTCATYTATGAYAG 500
FluC HE R1474 CTTTTGTYACACCTCCTCCTGAT 500
FluC HE R1511 TCATTTCCAATTTTYTCRAAYCC 500
FluC HE F1133 ATAAAGAAATGAGGGACYTGCTGT 500
Seq
FluC HE R1085 ATYARCATGCACCCTGGAGTG 500
HE fragment 3
FluC HE F1327 ACTGATACCACTGTAACCAAACCYAA 500
nPCR
FluC HE F1338 TGTAACCAAACCYAARAGCAGRAT 500
FluC HE R2067 AGCAAGGGGATTTTTGTTTTTYATAA 500
FluC HE R2073 AGCAGTAGCAAGGGGWTTTTTGT 500
FluC HE F1703 TGTGGGAACTAGCTTCAGAAATAAC 500
Seq
FluC HE R1663 AGGCTCTTATTATYCCCAATTCTCC 500
cDNA synthesis Uni11 AGCAGAAGCAG 1,000 Seq
BHQ1: black hole quencher 1; FAM: fluorescein amidite; FCV: feline calicivirus; HE: haemagglutinin esterase; IC: internal control; LC610: 
LightCycler 610; NP: nucleoprotein; nPCR: nested PCR; qPCR: quantitative/real-time PCR; seq: sequencing.
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N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
(HEPES) buffer with 5,000U/mL PenStrep) was added 
to the swabs (Copan Diagnostics, Murrieta, United 
States (US)) to wash out the attached viruses.
RNA was extracted from 200µL sample material using 
the MagNaPure96 DNA and Viral NA Small Volume Kit 
(Roche, Basel, Switzerland) and eluted in 50µL elution 
buffer.
In a total reaction volume of 20µL, 12.5µL of extracted 
RNA were subjected to cDNA synthesis applying ran-
dom hexamer primers and 200U Moloney murine leu-
kaemia virus (M-MLV) Reverse Transcriptase (Thermo 
Fisher Scientific, Waltham, US). Synthesised cDNA was 
diluted 1:1 with H2O to a total volume of 40µL to allow 
robotic pipetting of 384-well PCR plates.
For sequence analyses, cDNA was synthesised with the 
AccuScript Hi-Fi Reverse Transcriptase (Agilent, Santa 
Clara, US) and a primer that binds to the conserved 3’ 
end of the RNA gene segments (Uni11, see Table 1).
Real-time PCR
Real-time PCR (qPCR) for the detection of the influenza 
C nucleoprotein (NP) gene and feline calicivirus (FCV; 
internal control) was carried out on LC480II real-time 
PCR thermal cyclers (Roche, Basel, Switzerland) in 
a total reaction volume of 15µL in either a 96-well or 
384-well plate. The reaction contained 1x PCR buffer, 
4mmol/L MgCl2, 1mmol/L deoxynucleoside triphos-
phate (dNTP; Thermo Fisher Scientific, Waltham, US) 
with deoxyuridine triphosphate (dUTP; GE Healthcare, 
Chicago, US), 600ng bovine serum albumin (BSA; 
Thermo Fisher Scientific, Waltham, US), 0.3U (single-
plex) or 1U (duplex) Platinum Taq Polymerase (Thermo 
Fisher Scientific, Waltham, US), primers and probes as 
listed in Table 1 (Metabion, Planegg, Germany) [14,15], 
and 5µL of the prediluted cDNA. After 5 min at 95 °C 
for Taq DNA polymerase activation, a total of 45 cycles 
consisting of denaturation at 95 °C for 15 s and anneal-
ing at 60 °C for 30 s were performed. After the run, data 
were analysed using the LightCycler software version 
1.5.1.62.
Real-time PCR validation
Assay validation was performed with synthetic double 
stranded DNA strings (gBlocks; IDT, Skokie, US) in sin-
gleplex as well as duplex format (including the internal 
control FCV) on 96-well as well as 384-well plates.
For the determination of the linear detection range and 
the correlation (R2) of quantification cycle (Cq) values, a 
10-fold dilution series (106–101 copies per reaction) was 
examined in duplicates. PCR efficiency was calculated 
by inserting the slope value of the standard curve into 
the formula E = 10(-1/slope)-1.
The limit of detection (LOD) was established as 95% 
detection probability, calculated by probit analyses of 
the results of a 10-fold examination of low copy num-
bers (50–0.1 genome equivalents per reaction) apply-
ing the IBM SPSS Statistics 20 software.
For intraassay precision, gBlocks were examined six-
fold in a single run, while for interassay precision the 
intraassay data were extended by two additional runs 
with double reactions. All reproducibility runs were 
performed on consecutive days in independent experi-
ments, and precision was described as standard devia-
tion of the observed Cqvalues.
Specificity was ensured by the examination of a num-
ber of respiratory viruses (influenza A subtypes A(H1N1)
pdm09, A(H1N1) (circulating until 2009), A(H3N2), 
A(H7N9), A(H5N1), A(H5N8), influenza B, HRV, HMPV, 
RSV types A and B, adenovirus types B3 and C1, human 
coronaviruses NL63, 229E, OC43 and MERS coronavi-
rus, parainfluenza virus types 1–4, enterovirus D68) 
as well as Staphylococcus aureus and human genomic 
DNA.
Sequence determination
Conventional PCR for sequence determination of the HE 
gene was carried out in a total reaction volume of 50µL. 
The reaction contained 1x ExTaq buffer, 1.25mmol/L 
dNTP (Thermo Fisher Scientific, Waltham, US) with dUTP 
(GE Healthcare, Chicago, US), 1.25U ExTaq Polymerase 
(TaKaRa, Kusatsu, Japan), 500nM primers (Metabion, 
Planegg, Germany) as listed in  Table 1, and 5µL of 
the prediluted cDNA. Alternatively, the SuperScript 
Table 2
Validation results for the influenza C qPCR assay
Assay Slope E R2
LOD 
 
(geq)
Reproducibility
Intraassay Interassay
500,000 5,000 50 500,000 5,000 50
FluC -3.58 90% 0.998 10.5 0.09 0.04 0.50 0.19 0.28 0.47
FluC + FCV (96-well) -3.32 100% 0.997 10.3 0.04 0.02 0.39 0.44 0.49 0.60
FluC + FCV (384-well) -3.35 99% 0.9895 13.5 0.14 0.03 0.32 0.22 0.17 0.32
qPCR: quantitative/real-time PCR; E: PCR efficiency; geq: genome equivalents; R2: correlation coefficient; LOD: limit of detection.
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Figure 1
Monthly distribution in 0–4 year-old children of (A) the number of samples tested for influenza C, as well as testing 
coverage among samples received by the surveillance system (B) the number of positive samples for influenza C and 
resulting positivity rate, Germany, 2012–2014 (n =1,570)a
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a A total of 1,588 throat or nasal swabs were considered. Of these, the 1,570 samples that gave a valid quantitative/real-time PCR result are 
shown in the Figure.
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III One-Step RT-PCR System with Platinum Taq High 
Fidelity (Thermo Fisher Scientific, Waltham, US) was 
used without modification of reaction conditions.
For each sample, three overlapping nested PCRs 
yielded amplicons that span the HE gene. They were 
sequenced after purification (MSB Spin PCRapace Kit 
and Invisorb Spin DNA Extraction Kit, Stratec biomedi-
cal, Birkenfeld, Germany) using the dye terminator 
chemistry (ABI-Prism Big Dye Terminators v3.1 Cycle 
Sequencing Kit, Thermo Fisher Scientific, Waltham, US) 
in a 3130xl Genetic Analyzer (Thermo Fisher Scientific, 
Waltham, US). Additional ‘internal’ sequencing prim-
ers (labelled ’Seq’ in  Table 1) were used for amplicon 
sequencing in cases where the nested PCR primers did 
not yield a sequence spanning the complete amplicon. 
All HE sequences were processed and assembled in the 
Geneious software before their deposition at the Global 
Initiative on Sharing All Influenza Data (GISAID;  www.
gisaid.org) database (EPI1183982–EPI1183998). The 
applied amino-acid numbering includes the signal 
peptide.
Phylogenetic analyses
All HE sequence analyses were performed with 
Geneious version 10.0.5. Multiple sequence align-
ments were compiled on the basis of the MAFFT algo-
rithm. The N-terminal sequences including the signal 
peptide sequence (MFFSLLLMLGLTEA [16]) as well 
as the C-terminal region with incomplete sequence 
information (last 13 nt including the stop codon) were 
excluded. The alignment for phylogenetic analyses 
thus covered the nt 43 to 1,955 of the complete cod-
ing sequence and was calculated including reference 
sequences downloaded from the GISAID database 
(see  Supplement S2). Maximum likelihood trees were 
constructed applying the HKY85 model and the SPR 
tree topology search. Branching reliability was esti-
mated by performing 1,000 bootstrap replicates. Trees 
were manually edited in Corel Draw X6.
 
Results
A qPCR assay for the detection of influenza C viruses 
was established as singleplex as well as duplex qPCR 
including our routine internal control FCV. The assay 
proved to be a robust and sensitive tool and further-
more did not show any cross-reactivity to a variety of 
viral respiratory pathogens and to human genomic DNA 
(validation results summarised in Table 2).
The duplex qPCR approach was applied to retrospec-
tively examine 1,588 throat or nasal swabs, of which 
1,570 samples gave valid qPCR results, i.e. yielded 
either an influenza C or a FCV signal (or both) in duplex 
qPCR runs. Twenty samples (1.3%) were found positive 
for influenza C virus RNA, with Cq values ranging from 
19 to 39. The positive samples predominantly were 
taken between October 2012 and April 2013, reaching 
an average positivity rate of 2.6% (16/604) in these 
months (0.7–7.1% per month,  Figure 1). Outside of 
this particular winter season, viruses were identified 
only sporadically with detection rates of 1.2% (3/249, 
January–April 2012) or 0.2% (1/414, October 2013–
April 2014). No virus detection was achieved from May 
to September of any year studied. Also, no particular 
age distribution could be observed (Figure 2).
All influenza C-positive samples were additionally 
examined by qPCR to identify other respiratory viruses. 
More than half of the influenza C-positive patients 
(11/20; 55%) proved to be co-infected with diverse 
other respiratory pathogens (Table 3), with influenza C 
Cq values covering the complete range of 19 to 39.
All 20 patients with influenza C virus infection reported 
fever and cough. Fifteen patients reported a maximum 
temperature between 38.5 °C and 40.2 °C, while for the 
remaining five patients the maximum temperature was 
not provided. Additionally, a sudden disease onset 
(18/20), rhinitis (18/20), sore throat (8/20) and mus-
cular pain and/or headache (6/20) were predominant 
symptoms. Clinical signs of pneumonia were reported 
for one patient with an influenza C Cq value of 25, but 
also low amounts of influenza A(H3N2) were detected 
in this sample. In patients with a sole influenza C virus 
infection, the sudden disease onset (7/9), the maxi-
mum fever (38.9 °C – 40.2 °C in 6 patients), rhinitis 
(8/9), sore throat (4/9) and muscular pain and/or head-
ache (2/9) were reported in similar proportions.
The sequencing of the HE gene was achieved for 17 
samples, of which three yielded only partial sequences. 
Two of the incomplete sequences covered a consecu-
tive stretch of 1,071 and 1,218 nt, respectively, while 
Figure 2
Influenza C positivity rates in samples in 0–4 year-old 
children by age group, Germany, 2012–2014 (n = 1,570 
samples)a
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a A total of 1,588 throat or nasal swabs were considered. Of these, 
the 1,570 samples that gave a valid quantitative/real-time PCR 
result are shown in the Figure.
6 www.eurosurveillance.org
the third sequence gave two individual fragments at 
the N- and C-terminus of the viral protein. With a length 
of 1,899 – 2,005 nt, all other sequences reached nearly 
the full length of the HE protein, and were therefore 
included into further analyses.
Phylogenetically, the vast majority of samples (12/14) 
clustered into both subclades of the C/Sao Paulo line-
age represented by C/Aichi/1/99 and C/Victoria/2/2012 
(Figure 3). Nine sequences add to a C/Aichi/1/99 sub-
group of only three samples from Japan, represented 
by C/Miyagi/6/2014 and – within the Sao Paulo line-
age – characterised by the amino-acid substitution 
K204N. These sequences were derived from samples 
collected between March 2012 and March 2013. Three 
sequences, dating from between November 2012 and 
March 2013, group into the C/Victoria/2/2012 clade 
that, within the Sao Paulo lineage, are sole carriers 
of the amino-acid substitution Q372K. However, both 
amino-acid substitutions K204N and Q372K can also 
be found in other influenza C lineages. Two of our viral 
sequences sampled in March 2012 and April 2014 clus-
ter into the Kanagawa-lineage and form a separate 
small subgroup carrying the amino acid substitution 
K75R.
The three incomplete sequences were only character-
ised based on the nt homologies to other sequences. 
The two fragments of sample 13–04691 (775nt, 557nt) 
are 100% identical to our sample sequence 13–04332, 
which belongs to the C/Victoria/2/2012 subgroup of 
the C/Sao Paulo clade. Similarly, sample sequence 
Table 3
Summary of patient and virus characteristics for influenza C-positive samples, Germany, 2012–2014 (n = 20 samples)
Sample ID Sex Age
Collection 
date 
 
month-year
Collected in Symptoms FluC Cq Lineage Isolate ID
a Co-infection 
(Cq)
12–02332b M 2y Mar-12 Thuringia ILI 27 SP EPI_ISL_300530 None
12–02562 M 3y Mar-12 Thuringia ILI 21 SP EPI_ISL_300531 PIV-3 (28)
12–02741 M 3y Mar-12 Saxony ILI 19 Ka EPI_ISL_300532 Influenza A(H3N2) (24)
13–00167 M 20m Oct-12 Thuringia ILI 19 SP EPI_ISL_300533 None
13–00231b F 18m Nov-12 Bremen ILI 35 NA NA PIV-3 (26), AdV (34)
13–00344b F 3m Nov-12 North Rhine-Westphalia ILI 22 SP EPI_ISL_300534 HRV (24)
13–00418 M 2y Nov-12 Hamburg ILI 25 SP EPI_ISL_300535 None
13–00498 M 3y Nov-12 Schleswig-Holstein ILI 30 SP EPI_ISL_300536 CoV OC43 (25)
13–00580b M 13m Nov-12 Thuringia ILI 19 SP EPI_ISL_300537 None
13–00631 F 3y Dec-12 Baden-Wuerttemberg ILI 35 SP EPI_ISL_300538
AdV (22), PIV-3 
(30)
13–01570b M 11m Jan-13 North Rhine-Westphalia ILI 36 NA NA None
13–03024 M 23m Feb-13 Berlin ARI 29 SP EPI_ISL_300539 None
13–03232 F 8m Feb-13 Rhineland-Palatinate ILI 39 NA NA RSV-A (23)
13–04022 M 19m Feb-13 North Rhine-Westphalia ILI 29 SP EPI_ISL_300540 None
13–04332 M 2y Mar-13 Brandenburg ILI 25 SP EPI_ISL_300541 Influenza B(Yam) (30)
13–04588 F 2y Mar-13 Hesse ILI, pneu 21 SP EPI_ISL_300542 Influenza A(H3N2) (35)
13–04691b F 18m Mar-13 Brandenburg ILI 25 SP EPI_ISL_300543 HRV (32)
13–05206 M 13m Mar-13 Brandenburg ILI 26 SP EPI_ISL_300544 None
13–05486 F 12m Apr-13 Brandenburg ARI 33 SP EPI_ISL_300545 None
14–03242 M 3y Apr-14 Rhineland-Palatinate ILI 32 Ka EPI_ISL_300546 AdV (19)
AdV: adenovirus; ARI: acute respiratory infection; CoV: coronavirus; Cq: quantification cycle; F: female; FluC: influenza C virus real-time 
PCR; HRV: human rhinovirus; GISAID: Global Initiative on Sharing All Influenza Data; ILI: influenza-like illness; Ka: Kanagawa; M: male; m: 
months; NA: not available (the sequence could not be obtained); PIV: parainfluenza virus; pneu: pneumonia; RSV: respiratory syncytial 
virus; SP: Sao Paulo; Yam: Yamagata lineage; y: years.
a Deposited at Global Initiative on Sharing All Influenza Data (GISAID).
b ‘Group(add)’ sample according to sampling scheme explained in Supplement S1.
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13–05486 (1,037nt) is 100% identical to the sequence 
of C/Sao Paulo samples 13–04022 and 13–05206, 
which group into the C/Miyagi/6/2014 subgroup of the 
C/Aichi/1/99 subclade. Sample sequence 13–00631 
has a similarity of > 99.2% to the same Sao Paulo lin-
eage cluster, while the similarity to C/Victoria/2/2012 
(98.1%) and the prototype strain sequences for the 
other five HE lineages is lower (≤ 95.4%).
Discussion
Although influenza C virus was discovered 70 years 
ago, there is only little knowledge on the biology and 
epidemiology of this virus type. Some studies indi-
cated a low clinical impact with only mild symptoms 
[2,3,17], and in spite of a high seroprevalence in the 
population, virus detections were rare [6,11,18]. These 
findings led to the conclusion that influenza C infec-
tion is common, but clinically inapparent or too mild 
to require a visit to a doctor [2]. Additionally, the low 
detection rate may be in part due to the fact that in 
earlier times virus diagnostics were mainly based on 
virus culture, which is difficult for influenza C [6,19] 
and necessitates conditions that differ from influenza 
A and B virus cultivation [20]. As a consequence, influ-
enza C virus diagnostics were restricted to specialised 
laboratories and correspondingly rare [4].
With the introduction of molecular methods, influenza 
C has been increasingly included into studies on res-
piratory pathogens and clinical diagnostics. Thereby, 
the low detection rates in the general population were 
confirmed, but a higher clinical impact for paediatric 
patients was indicated, as influenza C was described 
to also cause lower respiratory tract disease [6-10]. In 
a 6-month prospective study (December 2009–May 
2010) including Japanese children with community-
acquired pneumonia, bronchiolitis or bronchitis, influ-
enza C infection was identified even with a prevalence 
approximating those of influenza A or HMPV [5]. Further 
studies, mostly in children, described the symptoms of 
influenza C infection to be indistinguishable from influ-
enza A and B infections [4,6], although the maximum 
body temperature may be lower and the fever shorter 
compared with influenza A [6,21,22]. In Finnish military 
recruits, influenza C virus caused common cold-like 
symptoms, but occasionally resulted in pneumonia and 
bronchitis [3].
For Europe, only little information on influenza C circu-
lation has been published. In adults, a seroprevalence 
of ca 70% and more was found in France [23], Finland 
[3], and United Kingdom [17]. Applying PCR on samples 
from all age groups, a virus detection rate of ≤ 1% was 
reported for Normandy/France [10], Scotland [24] and 
Spain [21], but higher detection rates of 3.5 – 4.2% 
were found in two adult studies from Finland [3,25]. 
Outside Europe, a similar seroprevalence as well as 
comparable detection rates have been described for 
Australia, Canada, Japan, Nigeria, the Philippines, Peru 
and the US [6-8,11,15,18,19,22,26-28].
In view of the lack of knowledge on influenza C virus 
circulation in Germany, we decided to generate the first 
systematic data on the basis of our national influenza 
virus surveillance. We chose to examine the age group 
of 0–4 years, as young children have been shown to 
have the highest infection rates [6,7,11,19]. We analysed 
a representative subset of the 2,377 samples received 
in this age group between 2012 and 2014 (52.1 – 100% 
of all samples in the corresponding month).
First, we validated a previously published qPCR [15] 
and duplexed it with our routine internal control, FCV. 
In an extensive validation effort according to interna-
tional standards [29], we found the singleplex as well 
as the duplex format to perform with high sensitivity, 
specificity and precision. We therefore applied it to our 
sample compilation and identified influenza C RNA in 
20 of 1,570 samples with valid qPCR results (1.3%). The 
vast majority of virus detections (16 of 20) was found 
in samples that were collected between October 2012 
and April 2013, signalling a more pronounced virus cir-
culation during these months with positivity rates of 
up to 7.1% (5/70) in November 2012. As these samples 
were collected in 10 of 16 German federal states, virus 
circulation was not confined to a region, but wide-
spread, maybe even nationwide. The virus prevalence 
however was markedly lower during the other winter 
seasons observed in this study, and no virus could be 
detected during the summer months. This absence of 
summer circulation is in congruence with reports from 
Japan, France, Finland and Spain [3,4,6,10,25], but is 
in contradiction to a report from Catalonia in Spain, 
in which the majority of positive samples were taken 
in August and September of the observed time span 
[21]. An upsurge of influenza C virus circulation in the 
spring of 2013 was also observed in the Philippines [8], 
but did not occur in Japan, from where virus circulation 
in even numbered years was reported, including the 
years 2012 and 2014 [11,30]. However, a biennial pat-
tern of virus circulation with increased or time-shifted 
profile has also been described for other respiratory 
viruses in Germany [31,32] and therefore is conceiv-
able, but remains open in our study due to the short 
study period, which presents a limitation. In total, the 
proportion of influenza C-positive patients was small, 
but within the expected range. It needs to be empha-
sised though, that the obtained overall positivity rate 
is largely based on only few months during the winter 
season 2012/13 with substantial virus circulation in our 
study population.
Because of our limited access to clinical data, only 
few conclusions can be drawn with regard to the clini-
cal relevance of influenza C virus. The vast majority of 
patients (18/20) carrying the virus fulfilled the EU ILI 
definition. Although, due to our study design, there 
may be a bias to ILI cases during periods of influenza 
A and B virus circulation, our findings are in concord-
ance with other studies, in which ILI was described 
for the majority or all of influenza C infected patients 
[21,27]. Bronchitis or bronchiolitis was not reported 
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Figure 3
Phylogenetic analyses of haemagglutinin esterase genetic sequences derived from influenza C-positive samples in 0–4 year-
old children using a set of representative sequences from different lineages, Germany, 2012–2014
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for any patient, but one child (infected also with an 
influenza A virus) presented with symptoms of pneu-
monia. However, the proportion of pneumonia in our 
influenza C-positive samples does not differ consider-
ably from that of our complete sample collection of this 
age group spanning the years 1999 to 2017 (data not 
shown). In our ambulant setting, we thus do not see 
an indication for an accumulation of lower respiratory 
tract disease in influenza C infected patients, but an 
influenza-like clinical presentation is common.
Interestingly, a substantial share of influenza C-positive 
samples showed co-infection with other pathogens, 
as reported also in other studies [3,4,15,27]. In these 
cases, the cause for ILI symptoms cannot clearly be 
attributed to influenza C. Yet, we used qPCR assays 
with comparable performance characteristics (LOD 
and efficiency), so that a comparison of the obtained 
Cq values can be semiquantitatively interpreted for the 
different pathogens within one sample. In our study, 
the majority of co-infected samples (6/11; 54.5%) 
exhibited the highest viral load for influenza C, includ-
ing the pneumonia case for whom it was ca 10,000-fold 
higher than that of influenza A at the time point and 
the sample site examined. In four samples, the influ-
enza C Cq  was close to the detection limit (≥ 35) and 
thus influenza C was presumably of minor relevance. 
Repetitive sampling from the same patients and 
continuous parallel assessment of the patients clinical 
presentation could clarify the role of the single patho-
gens in the disease course, but is not included in our 
routine influenza surveillance system. Therefore, we 
cannot judge on the temporal dynamics of virus rep-
lication and the clinical impact of each virus detected.
Due to the slow evolution and thus high antigenic 
homology of influenza C virus [11], we decided to char-
acterise the German sequences only on the basis of the 
HE gene sequences. The HE glycoprotein has a variety of 
functions in the viral replication cycle and greatly deter-
mines the antigenicity of the virus [33]. Based on anti-
genic and phylogenetic characteristics of this protein, 
distinct virus lineages have been described that were 
named after their prototype strains C/Taylor/1233/47, 
C/Kanagawa/1/76, C/Mississippi/80, C/Aichi/1/81, C/
Yamagata/26/81 and C/Sao Paulo/378/82 [30,34]. All 
influenza C lineage clusters are comprised of isolates 
from a multitude of continents, indicating a global 
circulation of virus lineages [34]. However, four line-
ages seemingly disappeared (C/Taylor, C/Aichi, C/
Mississippi, C/Yamagata), and only the C/Kanagawa 
and C/Sao Paulo lineage have been detected within the 
last decade [8,9,19,21,27,30,34].
From our positive samples, a total of 17 partial and near 
full-length HE sequences could be generated. We almost 
exclusively detected C/Sao Paulo lineage viruses, and 
only two C/Kanagawa viruses were identified. Our C/
Sao Paulo sequences add to both lineage subclades 
described by Matsuzaki et al. and represented by C/
Aichi/1/99 and C/Victoria/2/2012 [30]. A total of 11 
sequences (9 complete, 2 incomplete) group into the 
C/Aichi/1/99 subclade and were sampled between 
March 2012 and April 2013, while three additional 
sequences (2 complete, 1 incomplete) group into the C/
Victoria/2/2012 subclade and were sampled between 
November 2012 and March 2013. Thus, viruses of both 
subclades co-circulated during the 2012/13 winter sea-
son. In contrast, the two C/Kanagawa lineage viruses 
were sampled in March 2012 and April 2014, thus 
outside of the period with increased infection rates. 
They form a distinct cluster within the C/Kanagawa 
clade, most closely related to C/Miyagi/9/96. Both C/
Kanagawa viruses are almost identical to each other 
showing a nt homology of 99.1%, although they were 
sampled with a 2-year distance. Their closest neigh-
bour, C/Miyagi/9/96 even has a homology of 99.5% 
and 99.3% on the nt level. This further supports the 
described genetic stability of this virus type compared 
with influenza A and B viruses [30], possibly also 
reflecting their antigenic properties.
To summarise, our study is the first report on influ-
enza C circulation in the context of a nationwide out-
patient influenza surveillance system in Europe. We 
found influenza C in a proportion of samples that was 
in accordance with previous reports. An increased and 
widespread virus circulation was observed during the 
winter and spring months of 2012/13, with viruses pre-
dominantly belonging to C/Aichi/1/99 subclade of C/
Sao Paulo lineage viruses. Infected patients showed 
symptoms of ILI including upper as well as lower res-
piratory tract infection, although its association to the 
observed clinical symptoms remain uncertain in the 
majority of cases due to the identified co-infections. 
Further knowledge is needed about the virus epide-
miology, its transmission patterns, its role in sole and 
mixed infections as well as the associated disease 
burden, especially in young children and patients with 
lower respiratory tract disease.
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